HSP90AA1 and breast carcinoma: Furthermore, ROC curve identified plasma Hsp90α (AUC 0.7872, sensitivity 72.33%, specificity 71.95%, optimal cutoff 50.29 ng/mL) as a promising biomarker for differentiating early-stage breast cancer patients from the non-cancer control (Figure 1E and Table 1).